The Contraction of the Human Pulmonary Artery by LTC4 is Resistant to CYSLT1 Antagonists and Counteracted by Prostacyclin Release
The role of cysteinyl leukotrienes (cysLTs; LTC4LTD4 and LTE4) in asthma has been well established (Drazen et al., 1999). However, cysLTs also contract isolated human pulmonary vascular preparations (Schellenberg and Foster, 1984; Bourdillat et al., 1987; Labat et al., 1992; Ortiz et al., 1995) and have been proposed to be involved also in vascular pathologies, for example pulmonary hypertension (Stenmark et al., 1983). This suggestion has received support from animal studies (Davidson and Drafta, 1992) but the precise function of cysLTs in the pulmonary circulation remains to be established. Previous studies have raised support for at least two different receptors for cysLTs (Labat et al., 1992; Coleman et al., 1995; Bäck et al., 1996; Dahlén, 1998). Human bronchi contain CysLTI receptors (Buckner et al., 1986) that are targets for the clinically used anti-asthmatic CysLTI antagonists (Drazen et al., 1999). The receptor present on the human pulmonary venous smooth muscle is however resistant to CysLTI antagonists and
is referred to asCysLT 2 (Labat et al., 1992). This communication will report on cysLT effects in human pulmonary arterial preparationsin vitro.
KeywordsPulmonary Hypertension Pulmonary Circulation Primary Pulmonary Hypertension Human Airway Smooth Muscle Cell Human Bronchus
Unable to display preview. Download preview PDF.
- 2.Bourdillat, B., Haye-Legrand, I., Labat, C., Raffestin, B., Norel, X., Benveniste, J. and Brink, C., 1987, Effects of various pharmacological agents on isolated human bronchial and pulmonary arterial and venous muscle preparations contracted by LTDFundam Clin Pharmacol.1:433.PubMedCrossRefGoogle Scholar
- 4.Coleman, R.A., Eglen, R.M., Jones, R.L., Narumiya, S., Shimizu. T., Smith, W.L., Dahlén, S.E., Drazen, J.M., Gardiner, P.J., Jackson, W.T., Jones, T.R., Krell, R.D. and Nicosia, S., 1995, Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature.Adv Prostaglandin Thromboxane Leukot Res.23:283.PubMedGoogle Scholar
- 5.Dahlén, S.E., 1998, Leukotriene receptors: incompletely defined targets for treatment of asthma and inflammation, in:Five-lipoxygenase Products in AsthmaJ.M. Drazen, S.E. Dahlén, T.H. Lee, eds., Marcel Dekker, New York.Google Scholar
- 6.Davidson, D. and Drafta, D., 1992, Prolonged pulmonary hypertension caused by platelet-activating factor and leukotriene C4in the rat lungJAppl Physiol.73:955.Google Scholar
- 9.Jones, T.R., Zamboni, R., Belley, M., Champion, E., Charette, L., Ford-Hutchinson, A.W., Frenette, R., Gauthier, J.Y., Leger, S., Masson, P., McFarlane, C.S., Piechuta, H., Rokach, J., Williams, H., Young, R.N., DeHaven, R.N. and Pong, S.S., 1989, Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotrieneD4receptor antagonist,Can J Physiol Pharmacol.67:17.PubMedCrossRefGoogle Scholar
- 13.Panettieri, R.A., Tan, E.M., Ciocca, V., Luttmann, M.A., Leonard, T.B. & Hay, D.W., 1998, Effects of LTD, on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonistsAm J Respir Cell Mol Biol.19:453.PubMedCrossRefGoogle Scholar